An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Description

The purpose of this study is: 1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information 2. To evaluate the overall survival and leukemia-free survival of patients who discontinued placebo or pelabresib treatment in pelabresib parent studiesThe purpose of this study is to provide continued access to pelabresib treatment for patients who previously received pelabresib in a parent study and to continue collecting information on safety and efficacy. By collecting efficacy and safety information, the study team will monitor the efficacy of pelabresib with regard to disease status and survival, as well as information on AEs, including SAEs and AEs of special interest (AESIs), Additionally, survival follow-up data will be collected from patients who continued treatment with pelabresib in this extension study, and may also be collected from patients who discontinued treatment wit

Trial Eligibility

Inclusion Criteria: Eligibility for Ongoing Pelabresib Treatment 1. Capable of giving signed informed consent 2. Receiving clinical benefit from treatment with pelabresib in the parent study 3. Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures Eligibility for Survival Follow-up (Overall Survival and Leukemia-Free Survival) 1. Capable of giving signed informed consent Patient must be at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF 2. Patient has been enrolled in a clinical study with pelabresib 3. Willingness and ability to comply with ongoing follow-up as indicated in this protocol Exclusion Criteria: Eligibility for Ongoing Pelabresib Treatment 1. Patients who are legally institutionalized or under judicial protection 2. Any medical condition that, in the investigator's opinion, makes the patient unsuitable for the study 3. Patient is able to access pelabresib outside the study 4. Patient with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol 5. Female patients who are pregnant or breastfeeding Eligibility for Survival Follow-up (Overall Survival and Leukemia-Free Survival) 1. Patients who are legally institutionalized or under judicial protection

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.